Alcresta announced the availability of Relizorb (immobilized lipase), a novel digestive enzyme cartridge that hydrolyzes fats in enteral tube feeding formula to mimic normal pancreatic function. It is indicated for use in adult patients on enteral tube feeding who have trouble breaking down and absorbing fats. 

Relizorb was initially approved by the Food and Drug Administration (FDA) on December 11, 2015. This launch “will be focused on adults with cystic fibrosis who rely on enteral nutrition,” as approximately 90% of patients have fat malabsorption and 10–15% of patients depend on enteral feeding to meet their nutritional requirements. 

Related Articles

Relizorb was developed using the proprietary enzyme immobilization technology. Lipase, the active ingredient in Relizorb, is attached to polymeric carriers and is referred to as iLipase. As the enteral feeding formula passes through Relizorb, it comes in contact with iLipase and the fat is broken to its absorbable form (fatty acids and monoglycerides) before ingestion. Relizorb has demonstrated the ability to break down >90% of fats in most enteral feeding tube formulas that were tested, including the hard to break down long-chain polyunsaturated fatty acids (eg, docosahexaenoic acid [DHA], eicosapentaenoic acid [EPA], arachidonic acid [AA]). 

The formulas listed here have been evaluated for use with Relizorb.

For more information call (844) 735-4967 or visit